Limited-Time September Offer: Try 7 Days for Free

Ionis Pharmaceuticals (0JDI.L) Stock Price

$63.62 0.9%

Sign up
to add to portfolio

AI Score

  • Alternative

    7
  • Fundamental

    4
  • Technical

    8

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals. Scores are designed to reflect relative strength or weakness across these factors, helping users compare companies and track changes over time.

Sign up to get access to more historical data and insights on Ionis Pharmaceuticals, AI stock picks, stock alerts and much more.

Sign up

0JDI.L AI Stock Analysis

AI stock analysis for 0JDI.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Ionis Pharmaceuticals (0JDI.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Ionis Pharmaceuticals (0JDI.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Ionis Pharmaceuticals (0JDI.L), currently trading at $63.62, will... Sign up to access price prediction.

About 0JDI.L

LSE
  • Ionis Pharmaceuticals, Inc.

  • Symbol

    0JDI.L

  • Market

    LSE

  • Industry

    Medical - Pharmaceuticals

  • Market Cap

    10.1B

0JDI.L Alternative Data

Web Traffic

Ionis Pharmaceuticals receives an estimated 630 monthly visitors to ionispharma.com, which is down by -71.3% over the last month.

  • Web Traffic

    630

  • Change from Previous Month

    71.3%

  • 3 Month Change

    58.5%

  • YoY Change

    58.5%

Facebook Engagement

Ionis Pharmaceuticals has engaged 6 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    6

  • Daily Change

    14.3%

  • 1 Month Change

    84.2%

  • 3 Month Change

    50%

  • YoY Change

    50%

Youtube Subscribers

Ionis Pharmaceuticals has 188 subscribers on its main Youtube channel, up by 2.7% over the last month.

  • Youtube Subscribers

    188

  • Daily Change

    0%

  • 1 Month Change

    2.7%

  • 3 Month Change

    4.4%

  • YoY Change

    4.4%

Job Postings

Ionis Pharmaceuticals currenly has an estimated 55 open job postings, up by 3.8% over the last month.

  • Job Postings

    55

  • Daily Change

    77.4%

  • 1 Month Change

    3.8%

  • 3 Month Change

    111.5%

  • YoY Change

    111.5%

Reddit Mentions

Ionis Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Twitter Followers

Ionis Pharmaceuticals has 4,717 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.8% over the last month.

  • Twitter Followers

    4717

  • Daily Change

    0.1%

  • 1 Month Change

    0.8%

  • 3 Month Change

    1.8%

  • YoY Change

    1.8%

Instagram Followers

Ionis Pharmaceuticals has 428 Instagram Followers on its main Instagram account, up by 11.7% over the last month.

  • Instagram Followers

    428

  • Daily Change

    2.4%

  • 1 Month Change

    11.7%

  • 3 Month Change

    32.1%

  • YoY Change

    32.1%

LinkedIn Followers

88,261 are following Ionis Pharmaceuticals on LinkedIn, up by 2.6% over the last month.

  • LinkedIn Followers

    88261

  • Daily Change

    2.6%

  • 1 Month Change

    2.6%

  • 3 Month Change

    6.7%

  • YoY Change

    6.7%

Business Outlook

According to employee reviews, the business outlook among employees at Ionis Pharmaceuticals is 76 out of 100 (bullish).

  • Business Outlook

    76

  • Change from Previous Month

    0%

  • 3 Month Change

    9.5%

  • YoY Change

    9.5%

LinkedIn Employees

According to LinkedIn, Ionis Pharmaceuticals has 1,266 employees, up by 0.9% over the last month.

  • LinkedIn Employees

    1266

  • Daily Change

    0.9%

  • 1 Month Change

    0.9%

  • 3 Month Change

    4.6%

  • YoY Change

    4.6%

News Mentions

Ionis Pharmaceuticals was mentioned 1 times in the news yesterday.

  • News Mentions

    1

  • Daily Change

    66.7%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

0JDI.L Financials

0JDI.L Key Metrics
  • Total Revenue

    $131.6B

  • Net Income

    -$146.9M

  • Earnings per Share

    -$0.93

  • Free cash flow

    -$163.4B

  • EBITDA

    -$146.9B

  • EBITDA Ratio

    -1.11586

  • Total Assets

    $2812.9B

0JDI.L 2-year Revenue & Income
0JDI.L 2-year Free Cash Flow

0JDI.L Technicals

0JDI.L SMA
0JDI.L RSI

FAQ

What's the current price of Ionis Pharmaceuticals (0JDI.L) Stock?
The price of an Ionis Pharmaceuticals (0JDI.L) share is $63.62.

What's the market cap of Ionis Pharmaceuticals?
The current market cap of Ionis Pharmaceuticals is 10.1B.

What are some stocks similar to Ionis Pharmaceuticals (0JDI.L) that investors often compare it to?
Ionis Pharmaceuticals (0JDI.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Esperion Therapeutics.

What is the forecast for Ionis Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Ionis Pharmaceuticals' stock price to be around $67.83 in 2026. Starting from the current price of $63.62, this represents a 6.6% change in price, indicating a bullish outlook for the stock.

How to buy Ionis Pharmaceuticals (0JDI.L) Stock?
Ionis Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Ionis Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.